The other thing we should see in the next month is a report from the autism observational trial that is being done by EMD. Assuming this is is being contract managed from Zelira's end, we should have data from the first 12 month period and an indication whether they are going to extend the study. Hopefully they will as it will be an important data set and the cost into the future will only be for subscriptions. Last thing I remember about this is that it was fully enrolled but happy to hear if anyone has any more up to date info...
